Clinical and immunological features of severe and moderate coronavirus disease 2019

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, emerged in late 2019.
• Understanding the immunological differences between severe and moderate COVID-19 is crucial.

Purpose of the Study:

• To compare the immunological characteristics of patients with severe versus moderate COVID-19.
• To identify potential immunological markers associated with COVID-19 severity.

Main Methods:

• Retrospective analysis of clinical and immunological data from 21 COVID-19 patients.
• Classification of patients into severe (11) and moderate (10) groups based on national guidelines.
• Analysis of lymphocyte counts, cytokine levels (IL-2R, IL-6, IL-10, TNF-α), and IFN-γ expression.

Main Results:

• Severe cases showed higher rates of dyspnea, lymphopenia, and hypoalbuminemia.
• Elevated levels of inflammatory markers (CRP, ferritin, D-dimer) and cytokines were observed in severe cases.
• Markedly lower absolute counts of T lymphocytes, CD4+ T cells, and CD8+ T cells were found in severe cases compared to moderate cases.
• Reduced IFN-γ expression by CD4+ T cells was noted in severe COVID-19 patients.

Conclusions:

• SARS-CoV-2 infection significantly impacts T lymphocytes (CD4+ and CD8+).
• Decreased T cell numbers and impaired IFN-γ production are associated with severe COVID-19.
• These immunological changes serve as potential biomarkers for disease severity.